Jump to main content
Jump to site search


Supramolecular nanomedicine for selective cancer therapy via sequential responsiveness to reactive oxygen species and glutathione

Author affiliations

Abstract

Cancer cells are generally immersed in an oxidative stress environment with a high intracellular reduction level. Thus, nanocarriers with sequential responsiveness to oxidative and reductive species, matching the traits of high oxidation in the tumor tissue microenvironment and high reduction potential inside cancer cells, are highly desired for specific cancer therapy. Herein, we report a supramolecular nanomedicine comprised of a reduction-responsive nanoparticle (NP) core whose surface was modified by an oxidation-responsive polyethylene glycol (PEG) derivative via strong host–guest interactions. In this delicate design, the PEGylation of NPs not only reduced their immunogenicity and extended systemic circulation, but also enabled oxidation-responsive de-PEGylation in the tumor tissues and subsequent intracellular payload release in response to glutathione (GSH) inside tumor cells. As a proof of concept, this supramolecular nanomedicine exhibited specific chemotherapeutic effects against cancer in vitro and in vivo with a decent safety profile.

Graphical abstract: Supramolecular nanomedicine for selective cancer therapy via sequential responsiveness to reactive oxygen species and glutathione

Back to tab navigation

Supplementary files

Article information


Submitted
22 Oct 2020
Accepted
29 Nov 2020
First published
08 Dec 2020

Biomater. Sci., 2021, Advance Article
Article type
Paper

Supramolecular nanomedicine for selective cancer therapy via sequential responsiveness to reactive oxygen species and glutathione

C. Sun, Z. Wang, Z. Wang, L. Yue, Q. Cheng, Z. Ye, Q. Zhang and R. Wang, Biomater. Sci., 2021, Advance Article , DOI: 10.1039/D0BM01802C

Social activity

Search articles by author

Spotlight

Advertisements